Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Tandem Diabetes Care (TNDM) PT Lowered to $59 at Leerink Partners
November 7, 2024 5:57 AM ESTLeerink Partners analyst Mike Kratky lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $59.00 (from $62.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Despite posting another commanding topline beat (+9% vs. cons.), TNDM was bidding down high singledigits % post-market. We are... More
Tandem Diabetes (TNDM) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY24 Revenue Guidance
November 6, 2024 4:40 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $244 million versus the consensus estimate of $223.66 million.
GUIDANCE:
Tandem Diabetes sees FY2024 revenue of $903-910 million, versus the consensus... More
